Patent estate

EuroFarma — Patent Portfolio

1 drug with active patents · 4 active patents · 0 expired · 0 biologics with BPCIA exclusivity

AI-enriched 1/4 patents with grounded plain-English summaries · sourced from FDA Orange Book + Purple Book · updated 2026-05-18

Loss of exclusivity calendar · next 12 years

Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.

1 2027 1 2028

Patent estate by drug

Derma-Smoothe/Fs (FLUOCINOLONE ACETONIDE)

Cliff 2027 · 1y
Formulation 2 Method of Use 2
  • US9849027 Vuln 88 2028-11-07
    This patent protects an ocular implantation device with a housing, needle, plunger, and rod that work together to move an implant through the needle.
  • US7998108 Vuln 83 2028-01-12
  • US8871241 Vuln 60 2027-08-12
See all 4 patents →

Patent classification breakdown · active patents

By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.

  • Formulation 2 patents
  • Method of Use 2 patents

Sources

  • FDA Orange Book — small-molecule patents listed against approved NDAs.
  • FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
  • USPTO Patent Public Search — title, abstract, claim text grounding.
  • AI summaries generated by Drug Landscape, grounded in source claim text.

Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.

Track EuroFarma's patent estate

Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.

↓ CSV export